1. Scrip
  2. >>Therapy Areas

APPROVED: Genentech/Roche Gazyva 1st breakthrough-designated drug to enter US market

 
• By Donna Young

Roche US unit Genentech made history on 1 November as the first company to have an FDA-designated breakthrough therapy gain th agency’s blessing to enter the US market – Gazyva (obinutuzumab/GA101), which won approval in combination with chlorambucil as a therapy for treatment-naïve chronic lymphocytic leukemia (CLL).

Roche US unit Genentech made history on 1 November as the first company to have an FDA-designated breakthrough therapy gain th agency’s blessing to enter the US market – Gazyva (obinutuzumab/GA101), which won approval in combination with chlorambucil as a therapy for treatment-naïve chronic lymphocytic leukemia (CLL).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

Genentech To Try Repertoire’s Immune Synapse Technology In Autoimmune Disease

 
• By Joseph Haas

Deal snapshot: The Flagship portfolio firm will use its Decode platform to seek novel targets for an unspecified autoimmune disease, with Genentech holding license rights.

Sebela’s Tegoprazan Poised For GERD Market

 
• By Jessica Merrill

Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).

In Brief: DIOSynVax And ACM Biolabs To Develop Bird Flu Vaccine

 
• By Sushmita Panda

The collaboration, supported by UK and Singapore government agencies, aims to develop an mRNA-based, needle-free universal bird flu vaccine suitable for use in a pandemic.